Last Updated : May 19, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received Sort ascending | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Adcetris | Brentuximab vedotin | Hodgkin Lymphoma | Reimburse with clinical criteria and/or conditions | Complete | ||
| Rebif | Interferon beta-1a | Clinically isolated syndrome | Do not list | Complete | ||
| Jentadueto | Linagliptin-metformin | Diabetes mellitus, type 2 | List with criteria/condition | Complete | ||
| Afinitor | Everolimus | Renal angiomyolipoma associated with tuberous sclerosis complex (TSC) | Do not list | Complete | ||
| Fycompa | Perampanel | Epilepsy, partial onset seizures | List with criteria/condition | Complete | ||
| Edarbi | Azilsartan medoxomil | Hypertension | Do not list at the submitted price | Complete | ||
| Edarbyclor | Azilsartan medoxomil + chlorthalidone | Hypertension | Do not list | Complete | ||
| Myrbetriq | Mirabegron | Overactive bladder | Withdrawn | |||
| Sublinox | Zolpidem tartrate | Insomnia | Do not list | Complete | ||
| Xtandi | Enzalutamide | Metastatic Castration Resistant Prostate Cancer | Reimburse with clinical criteria and/or conditions | Complete |
Last Updated : May 19, 2024